牛牛AI助手已提取核心信息
AbbVie Inc. officer Perry C Siatias is set to sell 2,919 shares of the company's common stock on February 2, 2024, according to a recent filing. The shares, valued at approximately $496,230, were acquired on the same date through the exercise of stock options, with the issuer being the source of the securities. The transaction involved a cash payment made on the date of acquisition. There have been no other reported sales of securities by Siatias in the past three months, as per the provided documentation.
AbbVie Inc. officer Perry C Siatias is set to sell 2,919 shares of the company's common stock on February 2, 2024, according to a recent filing. The shares, valued at approximately $496,230, were acquired on the same date through the exercise of stock options, with the issuer being the source of the securities. The transaction involved a cash payment made on the date of acquisition. There have been no other reported sales of securities by Siatias in the past three months, as per the provided documentation.
根据最近的一份文件，艾伯维公司高管佩里·西亚蒂亚斯定于2024年2月2日出售该公司的2919股普通股。这些股票价值约496,230美元，于同日通过行使股票期权收购，发行人是证券的来源。该交易涉及在收购之日支付的现金。根据提供的文件，在过去三个月中，Siatias没有报告过其他证券销售情况。
根据最近的一份文件，艾伯维公司高管佩里·西亚蒂亚斯定于2024年2月2日出售该公司的2919股普通股。这些股票价值约496,230美元，于同日通过行使股票期权收购，发行人是证券的来源。该交易涉及在收购之日支付的现金。根据提供的文件，在过去三个月中，Siatias没有报告过其他证券销售情况。
有用
没用